Find drug development pipeline and deal Updates information

Lead Product(s): HMBD-002

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Hummingbird Bioscience

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 20, 2020

Details:

Pre-clinical studies have shown that HMBD-002 can strongly inhibit tumor growth, both as a monotherapy and even more potently when combined with anti-PD(L)1 treatment.